On Monday, TherapeuticsMD Inc (NYSEMKT:TXMD)’s shares declined -5.34% to $6.74.
TherapeuticsMD Inc (TXMD) declared that it will hold a conference call and live audio webcast to talk about first quarter 2015 financial and business results on Tuesday, May 5. The conference call and webcast will take place at 4:30 p.m. EDT. TherapeuticsMD CEO Robert G. Finizio and Chief Financial Officer Dan Cartwright will host the call.
TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, counting prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, in addition to duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.
Alkermes Plc (NASDAQ:ALKS)’s shares dropped -6.60% to $58.15.
Alkermes Plc (ALKS) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, April 30, 2015, to talk about the company’s first quarter 2015 financial results. Administration will also provide an update on the company.
Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas.
At the end of Monday’s trade, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)‘s shares dipped -6.55% to $62.02.
ISIS Pharmaceuticals, Inc. (ISIS) declared that administration will present a company overview at the following investor conferences:
14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 in New York, NY;
40th Annual Deutsche Bank Health Care Conference on Thursday, May 7, 2015 in Boston, MA;
2015 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 12, 2015 in Las Vegas; and
2015 UBS Global Healthcare Conference on Tuesday, May 19, 2015 in New York, NY.
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol.
SandRidge Energy Inc. (NYSE:SD), ended its Monday’s trading session with -6.52% loss, and closed at $1.72.
SandRidge Energy Inc. (SD) will release its 2015 first quarter shareholder update and financial results after the close of trading on the New York Stock Exchange on Wednesday, May 6, 2015.
The company will host a conference call to talk about these results on Thursday, May 7, 2015 at 8:00am CDT. The telephone number to access the conference call from within the U.S. is 877-201-0168 and from outside the U.S. is 647-788-4901.
SandRidge Energy, Inc., an oil and natural gas company, explores for and produces oil and natural gas properties primarily in the Mid-Continent region of the United States. The company operates through three segments: Exploration and Production, Drilling and Oil Field Services, and Midstream Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
